ReviewClinics in liver disease2012
The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.
Review in Clinics in liver disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis.Nutrients · 2020Pooled it
- Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.Journal of clinical gastroenterology · 2015Trial
- Noncoding RNA Transcripts Based Molecular Phenotyping of MASLD and MASH Patients.Liver international communications · 2026Article
- Review
- Diagnostic efficiency on ultrasound shear wave elastography in evaluation of steatosis severity for non-alcoholic fatty liver disease: a rat model.European journal of medical research · 2023Article
- Comparative Analysis of Global Hepatic Gene Expression in Adolescents and Adults with Non-alcoholic Fatty Liver Disease.Archives of clinical and biomedical research · 2023Article
- Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest.Entropy (Basel, Switzerland) · 2021Article
- Article
- Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease.BMC gastroenterology · 2019Article
- Fatty liver disease in persons with HIV infection.Topics in antiviral medicine · 2019Article
- Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic.Hepatology communications · 2017Review
- Characterization of transcriptional modules related to fibrosing-NAFLD progression.Scientific reports · 2017Article
- A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains.Scientific reports · 2017Article
- Characterisation of liver fat in the UK Biobank cohort.PloS one · 2017Article
- Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease.Current hepatology reports · 2016Article
- Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis.Gastroenterology research and practice · 2016Article
- Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients.BBA clinical · 2015Article
- Noninvasive imaging assessment of non-alcoholic fatty liver disease: focus on liver scintigraphy.World journal of gastroenterology · 2015Review
- Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis.Digestive diseases and sciences · 2015Article
- Micro RNAs in the development of non-alcoholic fatty liver disease.World journal of hepatology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Nonalcoholic fatty liver disease (NAFLD) has emerged as the most prevalent chronic liver disease. Nonalcoholic steatohepatitis (NASH), the more severe form of NAFLD, has an increased risk for progression to cirrhosis. The available data suggest increased morbidity and mortality among those patients with advanced histologic severity such as NASH and fibrosis. Despite the lack of a universally accepted histologic definition of NAFLD and inconsistency among pathologists regarding histologic findings essential to the diagnosis of NASH, a few studies have identified specific histologic findings (particularly fibrosis regardless of stage) that are able to predict NAFLD-related mortality as being most important.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.